X4 Pharmaceuticals Inc (NAS:XFOR)
$ 0.393 0.0036 (0.92%) Market Cap: 67.03 Mil Enterprise Value: 10.25 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 30/100

X4 Pharmaceuticals Inc 4WHIM Phase 3 Clinical Trial Update Call Transcript

May 16, 2023 / 08:00PM GMT
Release Date Price: $1.76 (+15.79%)
Operator

Good afternoon and welcome to the X4 Pharmaceuticals webinar. (Operator Instructions)

It is now my pleasure to introduce our host for the event, Dr. Paula Ragan, Founder, President, and Chief Executive Officer of X4 Pharmaceuticals.

Paula Ragan
X4 Pharmaceuticals, Inc. - CEO & President

Thank you, and thanks to all of you for joining us today to review and discuss the exciting data from our Phase 3 trial of mavorixafor in WHIM syndrome.

Before we begin, I'd like to remind everyone that on today's call, we will be making forward-looking statements regarding our regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent forms 10-K and 10-Q, both on file with the SEC.

We will begin today's program with a brief overview of our lead investigational candidate, mavorixafor, and its potential to address the many unmet needs of individuals with WHIM syndrome and our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot